Instil Bio, Inc.
TIL
$15.46
$0.1551.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.00% | -15.22% | -20.15% | -25.71% | -26.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.78% | -45.12% | -52.40% | -58.91% | -56.16% |
| Operating Income | 33.78% | 45.12% | 52.40% | 58.91% | 56.16% |
| Income Before Tax | 52.50% | 61.96% | 35.98% | 45.84% | 30.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.50% | 61.85% | 35.64% | 45.46% | 30.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.50% | 61.85% | 35.64% | 45.46% | 30.06% |
| EBIT | 33.78% | 45.12% | 52.40% | 58.91% | 56.16% |
| EBITDA | 34.31% | 45.80% | 52.92% | 59.56% | 57.22% |
| EPS Basic | 52.53% | 61.86% | 35.73% | 45.60% | 30.37% |
| Normalized Basic EPS | 30.83% | 41.97% | 49.18% | 59.13% | 57.60% |
| EPS Diluted | 52.53% | 61.87% | 35.73% | 45.60% | 30.37% |
| Normalized Diluted EPS | 30.83% | 41.97% | 49.18% | 59.13% | 57.60% |
| Average Basic Shares Outstanding | 0.09% | 0.04% | 0.12% | 0.25% | 0.44% |
| Average Diluted Shares Outstanding | 0.09% | 0.04% | 0.12% | 0.25% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |